Europe's Deeptech Future: Daphni Blue Fuels Science-Driven Startups
January 31, 2026, 3:38 pm
Daphni Blue closes its €260M fund, powering European deeptech. This capital ignites science-driven startups. The firm transforms cutting-edge lab research into impactful ventures. Focus areas span biology, physics, chemistry, and AI. The fund addresses major societal and environmental challenges. It signals robust investor confidence in Europe's scientific ecosystem. Early-stage innovations receive crucial backing. Daphni integrates financial success with strong ESG criteria. Europe's research strength now drives entrepreneurial breakthroughs.
Daphni, a French venture capital firm, has finalized its Blue fund. It secured €260 million. This significantly exceeded its initial target. The fund focuses on deeptech innovation. It aims to transform European scientific research into viable businesses. These new ventures will tackle pressing societal and environmental issues.
The fund closure happened swiftly. It took less than nine months. This indicates strong investor belief. Investor appetite for science-driven projects remains high. This despite a broader slowdown in the venture capital market. The Blue fund has already deployed capital. Nine deeptech companies have received investment. These firms originated from leading French research institutions. Institutes include INRIA, Institut Curie, INSERM, and Institut Langevin.
Daphni's model combines entrepreneurial community engagement. It also leverages a dedicated digital platform. This approach accelerates the lab-to-market transition. It highlights daphni's maturity in the deeptech space. It supports complex, long-term innovation.
The core belief of daphni Blue is clear. Next-generation technological breakthroughs will emerge from scientific intersections. Digital technologies, artificial intelligence, and the physical world converge. This requires sustained capital and specialized support. Bringing these innovations to market is the goal.
Europe produces vast intellectual property. Public and private research across various disciplines contributes. Biology, chemistry, physics, and mathematics are key fields. Commercial application of this research, however, lags. It often lacks sufficient funding and development. Daphni Blue addresses this gap. It converts scientific capital into entrepreneurial ventures. These ventures aim for both economic and societal value. This is a critical opportunity for European innovation.
Daphni Blue plans to back approximately 40 European companies. Past investments showcase daphni's experience. Companies like Epyr, Moonwatt, Pasqal, and Pruna AI demonstrate this. They were supported by previous daphni funds. Their success highlights the potential of science-based ventures.
The Blue fund's initial investments align with its mission. These include Owlo, EverDye, Karavela, and Neotis. Owlo originated from Institut Langevin. It develops real-time, non-invasive 3D microscopy technology. Applications span fertility and pharmaceutical research. EverDye advances patented textile dyeing. This technology uses green chemistry. It significantly reduces environmental impact. It is compatible with existing equipment.
Karavela spun out of INRIA. It develops a brain foundation model. This model utilizes functional MRI data. It enables new digital biomarkers. It also facilitates non-invasive brain-machine interfaces. Neotis pursues immunotherapeutic approaches. It targets pathological senescent cells. This aims to treat age-related chronic diseases. Its work is based on leading academic research. These investments exemplify the fund's deeptech focus.
The fund’s strategy is mission-driven. It targets both financial and non-financial performance. A portion of the fund’s carried interest links to ESG criteria. This ensures alignment between long-term impact and value creation. It reflects a dual commitment to returns and responsibility.
The broader European deeptech landscape shows momentum. Other funds also closed in late 2025 and early 2026. Copenhagen's Footprint Fund I secured €76 million. It targets climate and deeptech startups in Northern Europe. Berlin’s b2venture reached a €150 million hard cap. It launched its fifth fund. U2V, a spin-off from Earlybird-X, raised €60 million. This vehicle focuses on pre-Seed and Seed deeptech companies. These emerge from European technical universities. Lisbon’s Armilar Venture Partners raised €120 million. Its fourth fund invests in deeptech and digital transformation across Southern Europe.
Collectively, these funds represent significant capital flow. Approximately €666 million entered adjacent deeptech strategies. This occurred over 2025–2026. This trend highlights strong institutional appetite. Investors seek long-horizon, research-intensive innovation. Europe, particularly France, features prominently in this capital deployment.
Daphni’s new fund signals a strategic shift. Software and AI capabilities are increasingly commoditized. The firm bets on non-replicable assets. Deep scientific intellectual property forms this foundation. It is rooted in Europe’s public research system. This provides a distinct competitive advantage.
The fund targets 'scientist-entrepreneurs'. Their startups build on core research. Key scientific fields include biology, chemistry, physics, mathematics, and life sciences. Initial investment tickets range from €500k to €10 million. Follow-on investments can reach €20 million. The fund aims to support 40 to 50 companies over its lifecycle.
Europe boasts 2.2 million researchers. Its public research infrastructure is robust. This provides a major advantage for science-based investing. Daphni sees Europe leading this deeptech shift. The continent possesses the depth required for global impact.
Daphni positions itself beyond traditional venture capital. It acts as a bridge. It connects the scientific bench to the entrepreneurial world. This scale provides Europe's best minds a chance. They can build globally significant companies. The firm is shaping the future of European innovation. It backs ventures that drive progress. It creates both economic growth and positive societal change.
Daphni, a French venture capital firm, has finalized its Blue fund. It secured €260 million. This significantly exceeded its initial target. The fund focuses on deeptech innovation. It aims to transform European scientific research into viable businesses. These new ventures will tackle pressing societal and environmental issues.
The fund closure happened swiftly. It took less than nine months. This indicates strong investor belief. Investor appetite for science-driven projects remains high. This despite a broader slowdown in the venture capital market. The Blue fund has already deployed capital. Nine deeptech companies have received investment. These firms originated from leading French research institutions. Institutes include INRIA, Institut Curie, INSERM, and Institut Langevin.
Daphni's model combines entrepreneurial community engagement. It also leverages a dedicated digital platform. This approach accelerates the lab-to-market transition. It highlights daphni's maturity in the deeptech space. It supports complex, long-term innovation.
The core belief of daphni Blue is clear. Next-generation technological breakthroughs will emerge from scientific intersections. Digital technologies, artificial intelligence, and the physical world converge. This requires sustained capital and specialized support. Bringing these innovations to market is the goal.
Europe produces vast intellectual property. Public and private research across various disciplines contributes. Biology, chemistry, physics, and mathematics are key fields. Commercial application of this research, however, lags. It often lacks sufficient funding and development. Daphni Blue addresses this gap. It converts scientific capital into entrepreneurial ventures. These ventures aim for both economic and societal value. This is a critical opportunity for European innovation.
Daphni Blue plans to back approximately 40 European companies. Past investments showcase daphni's experience. Companies like Epyr, Moonwatt, Pasqal, and Pruna AI demonstrate this. They were supported by previous daphni funds. Their success highlights the potential of science-based ventures.
The Blue fund's initial investments align with its mission. These include Owlo, EverDye, Karavela, and Neotis. Owlo originated from Institut Langevin. It develops real-time, non-invasive 3D microscopy technology. Applications span fertility and pharmaceutical research. EverDye advances patented textile dyeing. This technology uses green chemistry. It significantly reduces environmental impact. It is compatible with existing equipment.
Karavela spun out of INRIA. It develops a brain foundation model. This model utilizes functional MRI data. It enables new digital biomarkers. It also facilitates non-invasive brain-machine interfaces. Neotis pursues immunotherapeutic approaches. It targets pathological senescent cells. This aims to treat age-related chronic diseases. Its work is based on leading academic research. These investments exemplify the fund's deeptech focus.
The fund’s strategy is mission-driven. It targets both financial and non-financial performance. A portion of the fund’s carried interest links to ESG criteria. This ensures alignment between long-term impact and value creation. It reflects a dual commitment to returns and responsibility.
The broader European deeptech landscape shows momentum. Other funds also closed in late 2025 and early 2026. Copenhagen's Footprint Fund I secured €76 million. It targets climate and deeptech startups in Northern Europe. Berlin’s b2venture reached a €150 million hard cap. It launched its fifth fund. U2V, a spin-off from Earlybird-X, raised €60 million. This vehicle focuses on pre-Seed and Seed deeptech companies. These emerge from European technical universities. Lisbon’s Armilar Venture Partners raised €120 million. Its fourth fund invests in deeptech and digital transformation across Southern Europe.
Collectively, these funds represent significant capital flow. Approximately €666 million entered adjacent deeptech strategies. This occurred over 2025–2026. This trend highlights strong institutional appetite. Investors seek long-horizon, research-intensive innovation. Europe, particularly France, features prominently in this capital deployment.
Daphni’s new fund signals a strategic shift. Software and AI capabilities are increasingly commoditized. The firm bets on non-replicable assets. Deep scientific intellectual property forms this foundation. It is rooted in Europe’s public research system. This provides a distinct competitive advantage.
The fund targets 'scientist-entrepreneurs'. Their startups build on core research. Key scientific fields include biology, chemistry, physics, mathematics, and life sciences. Initial investment tickets range from €500k to €10 million. Follow-on investments can reach €20 million. The fund aims to support 40 to 50 companies over its lifecycle.
Europe boasts 2.2 million researchers. Its public research infrastructure is robust. This provides a major advantage for science-based investing. Daphni sees Europe leading this deeptech shift. The continent possesses the depth required for global impact.
Daphni positions itself beyond traditional venture capital. It acts as a bridge. It connects the scientific bench to the entrepreneurial world. This scale provides Europe's best minds a chance. They can build globally significant companies. The firm is shaping the future of European innovation. It backs ventures that drive progress. It creates both economic growth and positive societal change.